Clene's CNM-Au8® Updates and Investor Conference Participation FAQ

What is CNM-Au8® and what does it do?

CNM-Au8® is Clene’s lead drug candidate designed to restore and protect neurological function, offering new hope for patients with ALS and other neurodegenerative conditions.

Why is Clene presenting at investor conferences?

Clene is presenting at investor conferences to share its latest achievements and updates on CNM-Au8®, aiming to optimize investor awareness and recognition.

When and where are these investor conferences taking place?

Clene participated in the 2024 Maxim Healthcare Virtual Summit on October 15 and will present at The ThinkEquity Conference 2024 at the Mandarin Oriental Hotel in New York on October 30.

What is the significance of CNM-Au8® for ALS patients?

CNM-Au8® has shown potential to restore and protect neurological function, which could significantly improve the quality of life for ALS patients, and Clene is seeking an accelerated FDA approval pathway for its use in ALS treatment.

How does Clene plan to advance CNM-Au8® towards FDA approval?

Clene is scheduled to meet with FDA leadership in November to discuss an accelerated approval pathway for CNM-Au8® for the treatment of ALS.

Where can I find more information about Clene and CNM-Au8®?

More information about Clene and CNM-Au8® can be found in the company’s newsroom at https://ibn.fm/CLNN and through their corporate communications at IBN (InvestorBrandNetwork).

Who is involved in the development and presentation of CNM-Au8®?

Clene Inc. and its wholly owned subsidiary, Clene Nanomedicine Inc., are involved in the development of CNM-Au8®, with presentations being made by the company’s executives at investor conferences.

What are the next steps for CNM-Au8®?

The next steps include Clene’s meeting with FDA leadership in November to discuss the accelerated approval pathway for CNM-Au8® for ALS treatment and continued participation in investor conferences to share updates.